Node_negative_breast_cancer:_the_prognostic_value_of_DNA_ploidy_for_long-term_survival._The_DNA_content_of_breast_tumours_from_170_patients_who_presented_between_1978_and_1980_was_measured_by_flow_cytometry._The_relationship_between_tumour_ploidy_and_disease_outcome_was_assessed_and_its_association_with_other_prognostic_factors_evaluated._Compared_with_those_with_diploid_tumours,_patients_with_aneuploid_tumours_had_significantly_earlier_relapse_and_shorter_survival_(P_less_than_0.0001)._Tumour_ploidy_was_strongly_related_to_grade_(P_less_than_0.001),_but_there_was_no_significant_association_between_DNA_ploidy_and_c-erb-B-2_expression,_lymph_node_status_or_tumour_size._In_lymph_node_negative_and_c-erb-B-2_negative_patients,_aneuploid_tumours_were_associated_with_a_poorer_prognosis_(P_less_than_0.001)_than_diploid_tumours._Multivariate_analysis_showed_that_tumour_ploidy_gave_independent_information_on_disease_free_and_overall_survival._Tumour_ploidy_may_be_used_as_an_independent_prognostic_variable_in_patients_with_breast_cancer_and_it_may_be_helpful_in_defining_patients_within_the_node_negative_or_c-erb-B-2_negative_groups_likely_to_have_a_poor_outcome_who_might_benefit_from_adjuvant_treatment.